Login / Signup

Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.

Siegfried KohlerStefanie MärschenzUlrike GrittnerTobias AlexanderFalk HiepeAndreas Meisel
Published in: BMJ open (2019)
NCT02102594.
Keyphrases
  • double blind
  • study protocol
  • clinical trial
  • placebo controlled
  • multiple myeloma
  • open label
  • newly diagnosed
  • randomized controlled trial